A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma.

Trial Profile

A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2014

At a glance

  • Drugs CLR 1404 I-131 (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 19 Feb 2014 Status changed from not yet recruiting to withdrawn prior to recruitment, as per ClinicalTrials.gov record.
    • 09 Jul 2013 Planned initiation date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov record.
    • 09 Jul 2013 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top